These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Verona Pharma’s Eutuvera has seen a strong market entry, with over 4,600 prescribers. The company is optimistic about expanding into bronchiectasis and developing a fixed-dose combination product. A ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...